Document Detail


Real-world cost-effectiveness in chronic myeloid leukaemia: The price of success during four decades of development from non-targeted treatment to imatinib.
MedLine Citation:
PMID:  25139694     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Imatinib has revolutionized the treatment of chronic myeloid leukaemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on CML-patients diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-alpha/stem cell transplantation and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and QoL estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratios (ICER) between periods III and II was €52,700 per QALY gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to €22,300. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.
Authors:
Lotta Ohm; Adam Lundqvist; Paul Dickman; Martin Höglund; Ulf Persson; Leif Stenke; Katarina Steen Carlsson; Magnus Björkholm
Related Documents :
24054784 - Good environmental status of marine ecosystems: what is it and how do we know when we h...
24905644 - Mapping and monitoring high nature value farmlands: challenges in european landscapes.
18172764 - Modeling heart rate regulation--part ii: parameter identification and analysis.
6499134 - Effects of pericardial effusates of various conductivities on body-surface potentials i...
10877324 - A curve-free method for phase i clinical trials.
22549414 - Symmetrizer: algorithmic determination of point groups in nearly symmetric molecules.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-8-20
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2014 Aug 
Date Detail:
Created Date:  2014-8-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  1-16     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  OUTCOME OF PEDIATRIC PATIENTS WITH LYMPHOMA FOLLOWING STEM CELL TRANSPLANTATION: A single institutio...
Next Document:  Understanding the polar mechanism of the ene reaction. A DFT study.